about
VIRsiRNAdb: a curated database of experimentally validated viral siRNA/shRNAPrediction of Druggable Proteins Using Machine Learning and Systems Biology: A Mini-ReviewTherapeutic Oligonucleotides Targeting Liver Disease: TTR AmyloidosissiRNA Versus miRNA as Therapeutics for Gene SilencingMediator kinase module and human tumorigenesisBeyond DNA origami: the unfolding prospects of nucleic acid nanotechnologyRole of regulatory micro RNAs in type 2 diabetes mellitus-related inflammationNon-coding RNAs in lung cancerNoncoding RNAs: emerging players in muscular dystrophiesThe panorama of miRNA-mediated mechanisms in mammalian cellsMicelle-like nanoparticles as carriers for DNA and siRNASelf-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic NanoparticlesHydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse BrainAllele-specific silencing of mutant huntingtin in rodent brain and human stem cellsSTAT3 upregulates miR-92a to inhibit RECK expression and to promote invasiveness of lung cancer cellsProgress toward in vivo use of siRNAs-IIMolecular mechanisms of RNA interferenceCombinations in multimodality treatments and clinical outcomes during cancerRNA therapeutics: RNAi and antisense mechanisms and clinical applicationsCurrent progress and challenges in HIV gene therapyCharacterization and in vitro activity of a branched peptide boronic acid that interacts with HIV-1 RRE RNAGene silencing: a therapeutic approach to combat influenza virus infections.Acoustic Cavitation-Mediated Delivery of Small Interfering Ribonucleic Acids with Phase-Shift Nano-EmulsionsSonoporation using microbubbles promotes lipofectamine-mediated siRNA transduction to rat retina.Anti-HBV efficacy of combined siRNAs targeting viral gene and heat shock cognate 70.CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs.An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistronTrends in the Binding of Cell Penetrating Peptides to siRNA: A Molecular Docking Study.Production of cloned pigs with targeted attenuation of gene expression.RNA interference-based therapeutics for inherited long QT syndromesiRNA Delivery Strategies: A Comprehensive Review of Recent Developments.miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAsNanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension.miR-127-5p negatively regulates enterovirus 71 replication by directly targeting SCARB2Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-miRs from a liver-specific promoter.Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease TherapyProtection and Systemic Translocation of siRNA Following Oral Administration of Chitosan/siRNA Nanoparticles.The inducible blockage of RNAi reveals a role for polyunsaturated fatty acids in the regulation of dsRNA-endocytic capacity in Bactrocera dorsalis.RNAi-based gene therapy for dominant Limb Girdle Muscular Dystrophies.MicroRNA and epilepsy: profiling, functions and potential clinical applications.
P2860
Q24621942-5A119DBD-32EB-43E8-B1A5-B7EC2D691FB4Q26773093-2785AF2B-359A-4E5A-B87A-7FD8B13534F4Q26782089-5A9F3A55-4A36-41E8-AC4B-C54DA72D6429Q26786876-9A89E82F-97E0-4286-8440-3E1C53227EB8Q26800203-08479ED7-7EE0-46E9-A640-637688EC7EB9Q26822686-D139E569-00E0-4033-9194-7B0E2195ECA7Q26830676-D8536F83-3E9E-4139-80FA-B1945F37CFA1Q26866521-B0C09791-27DA-47F0-AFC5-C4D70FDF1ABDQ26996781-12D23AE0-8D05-4538-8D7E-399BD75817B8Q27001268-B7D2B464-9E16-45C4-BEBD-4919B9B590BFQ27001558-F5CE8F4F-DD51-4D57-AA36-656158287AC4Q27027078-4A84C6B3-2218-44D2-B1C3-0FC3DD56001BQ27317421-D043C999-6856-4303-8164-2DB57A715318Q27324212-1482ED7A-817B-4B2B-A1BE-1856D69780F6Q28118347-D40D4536-FFB6-4D8D-B184-92E45C3FA2F5Q28255877-A51AAA8A-9D58-46CD-8981-F6671DCE8EB1Q28290306-7B31F668-D486-48AE-85C0-F9A99960A575Q28468623-5CD9D197-AD3B-4AF5-9396-5D6474010783Q28829240-5C3B3346-A042-48E4-AF33-8F4C013496A2Q29393523-BCC7C105-F724-4B4B-8AEA-46C7FCF4D588Q30276963-729B463A-9760-4717-B184-97D87DBADB6CQ30370880-674D1A41-9C31-43CE-A368-D3B2EA7A4D04Q30378008-AECD2310-038F-4D95-8707-2E967F54423CQ30415851-14DC1C57-3D51-4842-901A-1A2E6D293F69Q30531035-7FA49864-E5C7-4D3B-BD56-C5AA8DA93DA1Q30742370-9FF6B29B-C071-46B8-9327-87561CA9A39EQ30835231-935A50B5-6D15-4D6B-BAE2-FB9EC8937D77Q30840924-4DC248BC-446B-4E82-881D-70CF9DB8A446Q31118763-46D45BFD-8B4D-4F42-B045-9F6719D8BBF1Q33166507-B341E0F2-1342-4E91-BB79-F99C5B92E578Q33611947-6A9B5A94-8EC8-4C91-AB83-E8BE5F44ACACQ33635585-3F990276-9276-4072-AF96-D2E0BEA6DEF7Q33737242-821F0FF6-A5D6-43A5-9895-A9A21C5531F1Q33762630-70D98A09-377C-4F80-A393-C639CE3FF936Q33791557-8B3305C9-E488-47F3-B054-D95A3EDC8514Q33834772-BC0242F9-B619-4111-A81D-D808DC3D6B98Q33902729-DD23288B-C041-4252-AA08-DB2F7639F979Q33911970-D9309CAD-BE66-424D-B886-ED5697965C1FQ33996884-4564140F-E7BF-45F8-BD7A-E9E905F33B4BQ34023217-651EF1B7-A32C-4412-93CE-7AEDC864C15C
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Current prospects for RNA interference-based therapies
@ast
Current prospects for RNA interference-based therapies
@en
Current prospects for RNA interference-based therapies
@nl
type
label
Current prospects for RNA interference-based therapies
@ast
Current prospects for RNA interference-based therapies
@en
Current prospects for RNA interference-based therapies
@nl
prefLabel
Current prospects for RNA interference-based therapies
@ast
Current prospects for RNA interference-based therapies
@en
Current prospects for RNA interference-based therapies
@nl
P2860
P3181
P356
P1476
Current prospects for RNA interference-based therapies
@en
P2093
Beverly L Davidson
P2860
P2888
P304
P3181
P356
10.1038/NRG2968
P407
P577
2011-05-01T00:00:00Z
P5875
P6179
1048606089